Company: BDRX
Filing Date: 2025-09-12
Form Type: 424B3
Source: 0001214659-25-013675
Chunk: 14

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-12
Form: 424B3
Chunk 14
---
-based payment charge                             |     |      |   |     |                   - |     |                   - |   |     |             - |     |               - |   |     |                       195 |   |     |                195 |   |
| Total contribution by and distributions to owners      |     |      |   |     |               2,436 |     |               4,510 |   |     |             - |     |             217 |   |     |                       195 |   |     |              7,358 |   |
| At June 30, 2024                                       |     |      |   |     |               8,689 |     |              91,242 |   |     |        53,003 |     |           3,674 |   |     |                  (147,880 | ) |     |              8,727 |   |

The accompanying notes
form part of these financial statements

| 15 |

Notes Forming Part of The Consolidated Unaudited Interim Financial Information

For the six month period ended June 30, 2025

| 1. | Basis of preparation |

The unaudited interim
consolidated financial information for the six months ended June 30, 2025 has been prepared following the recognition and measurement
principles of the International Financial Reporting Standards, International Accounting Standards and Interpretations (collectively IFRS)
issued by the International Accounting Standards Board (IASB), and as adopted by the UK and in accordance with International Accounting
Standard 34 Interim Financial Reporting (‘IAS 34’). The interim consolidated financial information does not include all the
information and disclosures required in the annual financial information and should be read in conjunction with the audited financial
statements for the year ended December 31, 2024.

The accounting
policies adopted are consistent with those of the previous financial year and corresponding interim reporting periods.

Book values approximate
to fair value at June 30, 2025, June 30, 2024 and 31 December 31, 2024.

The condensed interim
financial information contained in this interim statement does not constitute statutory financial statements as defined by section 434(3)
of the Companies Act 2006. The condensed interim financial information has not been audited. The comparative financial information for
the six months ended June 30, 2024 and the year ended December 31, 2024 in this interim